Evidence map›Paper›PMID 36505821›Full record

ArticleFrontiers in oncology2022

PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors.

H S Gabryś, L Basler, S Burgermeister, S Hogan, M Ahmadsei, M Pavic, M Bogowicz, D Vuong, S Tanadini-Lang, R Förster and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. IsCancers · 2024
    Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

H S GabryśDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
L BaslerDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
S BurgermeisterDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
S HoganDepartment of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
M AhmadseiDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
M PavicDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
M BogowiczDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
D VuongDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
S Tanadini-LangDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
R FörsterDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
K KuduraDepartment of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
M HuellnerDepartment of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
R DummerDepartment of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
M P LevesqueDepartment of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
M GuckenbergerDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
University Hospital of Zurich · CHUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This study evaluated pretreatment 2[18F]fluoro-2-deoxy-D-glucose (FDG)-PET/CT-based radiomic signatures for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibition (ICI). Material and method: Fifty-six consecutive metastatic melanoma patients treated with ICI and available imaging were included in the study and 330 metastatic lesions were individually, fully segmented on pre-treatment CT and FDG-PET imaging. Lesion hyperprogression (HPL) was defined as lesion progression according to RECIST 1.1 and doubling of tumor growth rate. Patient hyperprogression (PD-HPD) was defined as progressive disease (PD) according to RECIST 1.1 and presence of at least one HPL. Patient survival was evaluated with Kaplan-Meier curves. Mortality risk of PD-HPD status was assessed by estimation of hazard ratio (HR). Furthermore, we assessed with Fisher test and Mann-Whitney Results: PD-HPD patients constituted 57.1% of all PD patients. PD-HPD was negatively related to patient overall survival with HR=8.52 (95%CI 3.47-20.94). Sixty-nine lesions (20.9%) were identified as progressing at 3 months. Twenty-nine of these lesions were classified as hyperprogressive, thereby showing a HPL rate of 8.8%. CT-based, PET-based, and PET/CT-based models predicting HPL at three months after the start of treatment achieved testing AUC of 0.703 +/- 0.054, 0.516 +/- 0.061, and 0.704 +/- 0.070, respectively. The best performing models relied mostly on CT-based histogram features. Conclusions: FDG-PET/CT-based radiomic signatures yield potential for pretreatment prediction of lesion hyperprogression, which may contribute to reducing the risk of delayed treatment adaptation in metastatic melanoma patients treated with ICI.

Indexed as

hyperprogressionimmune checkpoint inhibitionmelanomaPET/CTradiomics

Identifiers

PMID36505821
PMCPMC9730880
OpenAlexW4309915606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.